High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The use of daptomycin in Gram-positive left-sided infective endocarditis (IE) has significantly increased. The purpose of this study was to assess the influence of high-dose daptomycin on the outcome of left-sided IE due to Gram-positive pathogens. This was a prospective cohort study based on 1,112 cases from the International Collaboration on Endocarditis (ICE)-Plus database and the ICE-Daptomycin Substudy database from 2008 to 2010. Among patients with left-sided IE due to Staphylococcus aureus , coagulase-negative staphylococci, and Enterococcus faecalis , we compared those treated with daptomycin (cohort A) to those treated with standard-of-care (SOC) antibiotics (cohort B). The primary outcome was in-hospital mortality. Time to clearance of bacteremia, 6-month mortality, and adverse events (AEs) ascribable to daptomycin were also assessed. There were 29 and 149 patients included in cohort A and cohort B, respectively. Baseline comorbidities did not differ between the two cohorts, except for a significantly higher prevalence of diabetes and previous episodes of IE among patients treated with daptomycin. The median daptomycin dose was 9.2 mg/kg of body weight/day. Two-thirds of the patients treated with daptomycin had failed a previous antibiotic regimen. In-hospital and 6-month mortalities were similar in the two cohorts. In cohort A, median time to clearance of methicillin-resistant S. aureus (MRSA) bacteremia was 1.0 day, irrespective of daptomycin dose, representing a significantly faster bacteremia clearance compared to SOC (1.0 versus 5.0 days; P < 0.01). Regimens with higher daptomycin doses were not associated with increased incidence of AEs. In conclusion, higher-dose daptomycin may be an effective and safe alternative to SOC in the treatment of left-sided IE due to common Gram-positive pathogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in an observational study, high-dose daptomycin (≈9 mg/kg per dose) for treatment of left-sided IE was as effective as standard-of-care therapy and cleared MRSA bacteremia significantly faster than did standard-ofcare treatment.155”
In the citing paper
“The emergence of organisms with decreased susceptibility to daptomycin was observed in ≈5% of daptomycin-treated patients.”
Citations
Cites
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Self-citationDurack, D. T., Lukes, A. S., Bright, D. K., & Service, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90143-0 · Cited by 2,572 · cited 1×
““Persistent bacteremia” was defined using Duke Endocarditis Service Criteria as persistence of positive blood cultures after 72 h of organism-specific targeted antibacterial treatment (22).”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Self-citationDaptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationAntibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
Arias, C. A., & Murray, B. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0804651 · Cited by 1,027 · cited 1×
“Additionally, the rate of antimicrobial resistance among common Gram-positive IE pathogens has increased (5, 6), creating an urgent need for antibiotics with activity against such resistant pathogens.”
BackgroundContemporary Clinical Profile and Outcome of Prosthetic Valve Endocarditis
Wang, A. (2007) · JAMA · doi:10.1001/jama.297.12.1354 · Cited by 703
Self-citationThe Perpetual Challenge of Infectious Diseases
Fauci, A. S., & Morens, D. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1108296 · Cited by 517 · cited 1×
“Additionally, the rate of antimicrobial resistance among common Gram-positive IE pathogens has increased (5, 6), creating an urgent need for antibiotics with activity against such resistant pathogens.”
BackgroundCui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Temporal Trends in Infective Endocarditis in the Context of Prophylaxis Guideline Modifications
Duval, X., Delahaye, F., Alla, F., Tattevin, P., Obadia, J.-F., Le Moing, V., Doco-Lecompte, T., Celard, M., Poyart, C., Strady, C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.029 · Cited by 383
A Systematic Review of Population-Based Studies of Infective Endocarditis
Tleyjeh, I. M., Abdel-Latif, A., Rahbi, H., Scott, C. G., Bailey, K. R., Steckelberg, J. M., Wilson, W. R., & Baddour, L. M. (2007) · Chest · doi:10.1378/chest.06-2048 · Cited by 324
Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C., & Eliopoulos, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1581-1585.2006 · Cited by 262
Thornhill, M. H., Dayer, M. J., Forde, J. M., Corey, G. R., Chu, V. H., Couper, D. J., & Lockhart, P. B. (2011) · BMJ · doi:10.1136/bmj.d2392 · Cited by 254
Self-citationde Sa, D. D. C., Tleyjeh, I. M., Anavekar, N. S., Schultz, J. C., Thomas, J. M., Lahr, B. D., Bachuwar, A., Pazdernik, M., Steckelberg, J. M., Wilson, W. R., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0585 · Cited by 216
Patel, J. B., Jevitt, L. A., Hageman, J., McDonald, L. C., & Tenover, F. C. (2006) · Clinical Infectious Diseases · doi:10.1086/504084 · Cited by 183
Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence
Deresinski, S. (2007) · Clinical Infectious Diseases · doi:10.1086/518452 · Cited by 173
Progress toward a global understanding of infective endocarditis
Cabell, C. H., & Abrutyn, E. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(01)00007-1 · Cited by 147 · cited 1×
“A case report form containing 275 variables, with additional variables for the ICE-Daptomycin Substudy, was developed by the ICE group according to standard definitions (17, 20, 21).”
MethodKullar, R., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.6.527 · Cited by 136 · cited 1×
“Nevertheless, the absence of a substantive increase in adverse events among patients treated with higher daptomycin doses ( 8 mg/kg/ day) calls for a reevaluation of the recommended dosage of daptomycin in the setting of IE, especially in left-sided IE (29).”
BackgroundDaptomycin Exerts Bactericidal Activity without Lysis of Staphylococcus aureus
Cotroneo, N., Harris, R., Perlmutter, N., Beveridge, T., & Silverman, J. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01410-07 · Cited by 128 · cited 1×
“We hypothesize that these findings are at least partly due to a faster bactericidal effect of daptomycin than the SOC comparator, vancomycin, which is known for its “slow bactericidal” effect in vitro (23, 24) and substantial clinical failure rate in vivo (25).”
BackgroundDaptomycin in the Treatment of Patients with Infective Endocarditis: Experience from a Registry
Levine, D. P., & Lamp, K. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.011 · Cited by 105
Segreti, J. A., Crank, C. W., & Finney, M. S. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.347 · Cited by 88 · cited 2×
“This finding correlates with our own clinical experience and with other reports (9, 13, 16) but must be interpreted in light of the small sample size of this study.”
MethodResultMortin, L. I., Li, T., Van Praagh, A. D. G., Zhang, S., Zhang, X.-X., & Alder, J. D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00738-06 · Cited by 80 · cited 1×
“We hypothesize that these findings are at least partly due to a faster bactericidal effect of daptomycin than the SOC comparator, vancomycin, which is known for its “slow bactericidal” effect in vitro (23, 24) and substantial clinical failure rate in vivo (25).”
BackgroundCrank, C. W., Scheetz, M. H., Brielmaier, B. D., Rose, W. E., Patel, G. P., Ritchie, D. J., & Segreti, J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.09.008 · Cited by 69
Daptomycin for the treatment of infective endocarditis: results from a European registry
Dohmen, P. M., Guleri, A., Capone, A., Utili, R., Seaton, R. A., Ramallo, V. J. G., Pathan, R., Heep, M., & Chaves, R. L. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks467 · Cited by 39 · cited 2×
“This finding correlates with our own clinical experience and with other reports (9, 13, 16) but must be interpreted in light of the small sample size of this study.”
MethodResultEndocarditis due to Corynebacterium amycolatum
Dalal, A., Urban, C. M., & Segal‐Maurer, S. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.2008/003343-0 · Cited by 36
Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci
Cervera, C., Castañeda, X., Pericàs, J. M., del Río, A., de la Mària, C. G., Mestres, C. A., Falces, C., Marco, F., Moreno, A., & Miró, J. M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.038 · Cited by 36
Self-citationHeart block and coronary artery disease.
Davies, M. J., Redwood, D. R., & Harris, A. (1967) · BMJ · doi:10.1136/bmj.3.5561.342 · Cited by 30
Nelson, M. R., & Hamilton, H. E. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.010 · Cited by 30
Use of daptomycin in complicated cases of infective endocarditis
Das, I., Saluja, T., & Steeds, R. P. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1160-y · Cited by 12
Treatment of Gram-positive left-sided infective endocarditis with daptomycin
Kaya, S., Yılmaz, G., Kalkan, A., Ertunç, B., & Köksal, İ. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0546-9 · Cited by 10 · cited 2×
“This finding correlates with our own clinical experience and with other reports (9, 13, 16) but must be interpreted in light of the small sample size of this study.”
MethodResult
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Self-citationHabib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citation2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Self-citationClinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
“Levine et al,45 1991 (openlabel RCT) Moderate 42 MRSA endocarditis (median [range] age of 32 [23-61] y); treatment with vancomycin alone (1 g every 12 h; n = 22) vs vancomycin (1 g every 12 h) plus rifampin (600 mg/d) (n = 20) Duration of bacteremia Median duration of 9 d for bacteremia for all patients; 7 (95% CI, 5…”
Self-citation
Metadata
- Authors
- Carugati, M., Bayer, A. S., Miró, J. M., Park, L. P., Guimarães, A. C., Skoutelis, A., Fortes, C. Q., Durante-Mangoni, E., Hannan, M. M., Nacinovich, F., Fernández-Hidalgo, N., Grossi, P., Tan, R.-S., Holland, T., Fowler, V. G., Corey, R. G., & Chu, V. H.
- Affiliations
- University of Milan (IT)
- University of California, Los Angeles (US)
- Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
- Duke Medical Center (US)
- Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil
- Evangelismos Hospital (GR)
- Clementino Fraga Filho Hospital, Rio de Janeiro, Brazil
- University of Naples S.U.N., Monaldi Hospital, Naples, Italy
- Mater Misericordiae University Hospital (IE)
- Instituto Cardiovascular de Buenos Aires (AR)
- Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
- University of Insubria (IT)
- National Heart Centre Singapore (SG)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-12
- Volume
- 57
- Issue
- 12
- Pages
- 6213-6222
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3837915
- OpenAlex
- W1978437183
- Cited by
- 100
- References
- 30
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 10 · 2016: 11 · 2015: 19 · 2014: 11
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (K24AI093969)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- daptomycin, high-dose daptomycin, left-sided endocarditis, Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, methicillin-resistant Staphylococcus aureus, bacteremia clearance, in-hospital mortality, adverse events, antibiotic treatment failure
- MeSH terms
- Aged, Anti-Bacterial Agents, Endocarditis, Bacterial, Female, Humans, Male, Middle Aged, Prospective Studies, Staphylococcus aureus, Enterococcus faecalis, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.